← SynDRA
Gsk-2606414
SynDRA canonical compound SYN0058646 — structure-anchored drug synonym record
| Clinical phase | Preclinical |
|---|
| Primary target(s) | EIF2AK3 | MYLK2 |
|---|
| Mechanism of action | protein kinase inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- protein kinase inhibitor
- MYLK2 INHIBITOR
- EIF2AK3 INHIBITOR
Cross-references
Synonyms
- GSK2606414
- GSK PERK Inhibitor
- 3-fluoro-GSK2606414
- compound 38 [PMID: 22827572]
- DPP2K6EFW8
- RefChem:106347
- MFCD25976926
- C24H20F3N5O
- SIXVRXARNAVBTC-UHFFFAOYSA-N
- CS-1428
- UNII-DPP2K6EFW8
- SCHEMBL868254
- orb1305265
- SCHEMBL29384284
- SCHEMBL29403654
- SCHEMBL30500616
- EX-A340
- CHEBI:232161
- HMS3653O10
- HMS3743C19
- BDBM50396534
- NSC781627
- s7307
- AKOS024458496
- CCG-269247
- EK-0047
- FG65036
- NSC-781627
- SB19408
- GSK2606414?
- NCGC00346070-03
- NCGC00346070-09
- AC-29016
- DA-33592
- HY-18072
- SY389505
- G7345
- SW219646-1
- BRD-K81689258-001-02-2
Look up Gsk-2606414 in the interactive SynDRA portal →